Drew Moghanaki, Professor, Chief of Thoracic Oncology at David Geffen School of Medicine at UCLA, shared on X:
“NEW: An update on the harmful consequences of neoadjuvant chemoimmunotherapy in poorly selected pts with stage III NSCLC.”
Title: Caution Against Uncritical Adoption of Neoadjuvant Chemoimmunotherapy Followed by Definitive Radiotherapy in Stages II to III NSCLC: In Response to Adib et al
Authors: Steven J. Feigenberg, Cole Friedes, Jeffrey D. Bradley.
Read the full article.
You might be interested in: Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable NSCLC: What This 2026 Meta-Analysis Really Shows
